Charlotte Harding of Petauri Evidence discusses whether faster regulatory and HTA decisions will speed patient access and what NHS adoption of innovative medicines requires.
The page describes ICER as an independent watchdog that published cost-effectiveness analyses cited by payers and criticized by manufacturers. Professional associations and medical societies developed guidelines for clinical decision-making.
The page says healthcare stakeholders in 2026 must translate evidence into operational, financial, and policy-relevant action, highlighting real-world evidence, decision-grade HEOR, and AI-enabled analytics.
Petauri Health unites market access, HEOR, medical communications and health system engagement specialists. One commercialization partner for pharma, biotech and medtech.
The site says it collects comment-form data, visitors’ IP addresses, and browser user agent strings for spam detection, as well as an anonymized string created from email addresses.
